• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者在启动改善病情抗风湿药物决策过程中的考量因素。

Patients' considerations in the decision-making process of initiating disease-modifying antirheumatic drugs.

作者信息

Nota Ingrid, Drossaert Constance H C, Taal Erik, van de Laar Mart A F J

机构信息

University of Twente, Enschede, The Netherlands.

Medisch Spectrum Twente and University of Twente, Enschede, The Netherlands.

出版信息

Arthritis Care Res (Hoboken). 2015 Jul;67(7):956-64. doi: 10.1002/acr.22531.

DOI:10.1002/acr.22531
PMID:25504789
Abstract

OBJECTIVE

To explore what considerations patients have when deciding about disease-modifying antirheumatic drugs (DMARDs) and what information patients need to participate in the decision-making process.

METHODS

In-depth face-to-face interviews were conducted with 32 patients with inflammatory arthritis who recently consulted their rheumatologist and discussed initiating DMARDs.

RESULTS

Beliefs in the necessity of DMARDs, either for relief of symptoms or prevention of future joint damage, were reasons to initiate DMARDs. Furthermore, trust in the rheumatologist and the health care system was important in this respect. Patients expressed many concerns about initiating DMARDS. These related to the perceived aggressive and harmful nature of DMARDs, potential (or unknown) side effects, influence on fertility and pregnancy, combination with other medicines, time to benefit, and manner of administration. Participants also worried about the future regarding long-term medication use and drug dependency, and if a medicine proved to be ineffective, about the risks of future treatments and running out of options. To decrease uncertainty, participants wanted to be informed about multiple treatment options, both current and future. They not only wanted clinical information but also information on how the medications could affect their daily lives.

CONCLUSION

Health education should inform patients about multiple treatment options, for the present as well as for the future. It should enable patients to compare treatments with regard to both clinical aspects as well as possible consequences for their daily lives.

摘要

目的

探讨患者在决定使用改善病情抗风湿药物(DMARDs)时会考虑哪些因素,以及患者参与决策过程需要哪些信息。

方法

对32例近期咨询过风湿病专家并讨论开始使用DMARDs的炎性关节炎患者进行了深入的面对面访谈。

结果

认为DMARDs对于缓解症状或预防未来关节损伤有必要,是开始使用DMARDs的原因。此外,在这方面,对风湿病专家和医疗保健系统的信任很重要。患者对开始使用DMARDs表达了许多担忧。这些担忧涉及DMARDs被认为具有的侵袭性和有害性、潜在(或未知)的副作用、对生育和妊娠的影响、与其他药物的联合使用、获益时间以及给药方式。参与者还担心长期用药和药物依赖的未来情况,以及如果一种药物被证明无效,未来治疗的风险和无药可用的情况。为了减少不确定性,参与者希望了解当前和未来的多种治疗选择。他们不仅想要临床信息,还想要了解药物如何影响他们日常生活的信息。

结论

健康教育应告知患者当前及未来的多种治疗选择。应使患者能够在临床方面以及对其日常生活可能产生的后果方面对治疗方法进行比较。

相似文献

1
Patients' considerations in the decision-making process of initiating disease-modifying antirheumatic drugs.患者在启动改善病情抗风湿药物决策过程中的考量因素。
Arthritis Care Res (Hoboken). 2015 Jul;67(7):956-64. doi: 10.1002/acr.22531.
2
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs.一种用于启动改善病情抗风湿药物的患者决策辅助工具的评估
Arthritis Res Ther. 2016 Oct 28;18(1):252. doi: 10.1186/s13075-016-1138-3.
3
Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.影响类风湿性关节炎患者对改善病情药物信念的因素。
Rheumatology (Oxford). 2004 May;43(5):583-6. doi: 10.1093/rheumatology/keh116. Epub 2004 Feb 17.
4
Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.类风湿关节炎患者在抗风湿药物治疗方面的决策:患者对医生信任的重要性。
J Rheumatol. 2008 Apr;35(4):618-24. Epub 2008 Feb 15.
5
Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis.治疗相关信息及参与决策:一项关于类风湿关节炎患者认知与偏好的定性研究
J Med Ethics. 2008 Nov;34(11):775-9. doi: 10.1136/jme.2007.023705.
6
Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods.使用以用户为中心的设计方法开发一种基于网络的患者决策辅助工具,用于启动改善病情抗风湿药物治疗。
BMC Med Inform Decis Mak. 2017 Apr 26;17(1):51. doi: 10.1186/s12911-017-0433-5.
7
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.疾病修正抗风湿药物能否在长期类风湿关节炎中停用?一项 15 年随访研究。
Scand J Rheumatol. 2010;39(1):12-8. doi: 10.3109/03009740903042394.
8
The complexity of the treatment: the decision-making process among women with rheumatoid arthritis.治疗的复杂性:类风湿关节炎女性患者的决策过程。
Qual Health Res. 2011 Feb;21(2):214-22. doi: 10.1177/1049732310381086. Epub 2010 Aug 26.
9
Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.类风湿关节炎患者的初始改善病情抗风湿药物和泼尼松龙处方:一项15年的研究
J Med Assoc Thai. 2000 Mar;83(3):217-24.
10
Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.类风湿关节炎患者使用非生物改善病情抗风湿药与感染风险
Arthritis Rheum. 2008 Aug 15;59(8):1074-81. doi: 10.1002/art.23913.

引用本文的文献

1
Exploring drug utilization patterns, healthcare resource utilization, and epidemiology of rheumatoid arthritis in Colombia: a retrospective claims database study.探索哥伦比亚类风湿性关节炎的药物使用模式、医疗资源利用情况及流行病学:一项回顾性索赔数据库研究。
BMC Rheumatol. 2025 Feb 7;9(1):13. doi: 10.1186/s41927-025-00459-1.
2
Co-Design of a Disease Activity Based Self-Management Approach for Patients with Rheumatoid Arthritis.类风湿关节炎患者基于疾病活动度的自我管理方法的协同设计
Mediterr J Rheumatol. 2021 Mar 31;32(1):21-30. doi: 10.31138/mjr.32.1.21. eCollection 2021 Mar.
3
"Walking into the unknown…" key challenges of pregnancy and early parenting with inflammatory arthritis: a systematic review and thematic synthesis of qualitative studies.
“步入未知领域……”:炎症性关节炎患者妊娠和育儿早期的关键挑战:一项定性研究的系统评价和主题综合分析。
Arthritis Res Ther. 2021 Apr 21;23(1):123. doi: 10.1186/s13075-021-02493-z.
4
What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review.类风湿关节炎患者对治疗调整的偏好有哪些?一项范围综述。
Patient. 2021 Sep;14(5):505-532. doi: 10.1007/s40271-020-00488-7. Epub 2020 Dec 18.
5
Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center.关于改善病情抗风湿药(DMARDs)的现实世界问题与担忧:对医学呼叫中心问题的回顾性分析
BMC Rheumatol. 2020 Jun 16;4:27. doi: 10.1186/s41927-020-00126-7. eCollection 2020.
6
Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines.《地中海东部区域类风湿关节炎管理建议:对 2015 年美国风湿病学会指南的扩展》。
Clin Rheumatol. 2018 Nov;37(11):2947-2959. doi: 10.1007/s10067-018-4245-5. Epub 2018 Aug 10.
7
Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review.自身免疫性风湿疾病患者的药物依从性和持续性:一篇叙述性综述
Patient Prefer Adherence. 2018 Jul 3;12:1151-1166. doi: 10.2147/PPA.S165101. eCollection 2018.
8
Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis.患者对类风湿关节炎和强直性脊柱炎中疾病修饰抗风湿药物的态度和体验:定性综合。
Arthritis Care Res (Hoboken). 2018 Apr;70(4):525-532. doi: 10.1002/acr.23329. Epub 2018 Mar 24.
9
Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens.类风湿关节炎患者接受或抵制疾病修正抗风湿药物治疗方案的动机。
Arthritis Care Res (Hoboken). 2018 Apr;70(4):533-541. doi: 10.1002/acr.23301. Epub 2018 Mar 11.
10
Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods.使用以用户为中心的设计方法开发一种基于网络的患者决策辅助工具,用于启动改善病情抗风湿药物治疗。
BMC Med Inform Decis Mak. 2017 Apr 26;17(1):51. doi: 10.1186/s12911-017-0433-5.